A Biotech Company Finds a Silver Lining After Clinical Trial Results Show Failure of its New ALS Drug
It has been less than two years since Cytokinetics’ previous ALS muscle drug, tirasemtiv, failed to meet its endpoint in a Phase III trial to treat ALS. (That was after…